Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000732513 | SCV000574135 | uncertain significance | not provided | 2017-03-21 | criteria provided, single submitter | clinical testing | The E217G variant in the MMACHC gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The E217G variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The E217G variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved in mammals. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret E217G as a variant of uncertain significance. |
Eurofins Ntd Llc |
RCV000732513 | SCV000860479 | uncertain significance | not provided | 2018-03-19 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001834577 | SCV004178221 | uncertain significance | Cobalamin C disease | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000732513 | SCV005186678 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001834577 | SCV002089554 | uncertain significance | Cobalamin C disease | 2020-08-03 | no assertion criteria provided | clinical testing |